ProCE Banner Activity

Promising Developments in AML From ASH 2018

Conference Coverage
Clinical Thought
At ASH 2018, exciting new data were presented on targeted therapy–based regimens for patients with newly diagnosed AML or unfit for conventional chemotherapy along with data on novel immunotherapies.

Released: December 27, 2018

Expiration: December 26, 2019

No longer available for credit.

Share

Faculty

Gary J. Schiller

Gary J. Schiller, MD

Professor
Division of Hematology/Oncology
Department of Medicine
Director, Hematological Malignancy/Stem Cell Transplantation
David Geffen School of Medicine at UCLA
Los Angeles, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by educational grants from

Actinium

Astellas Text

Boston Biomedical

Celgene

Daiichi Sankyo, Inc.

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Gary J. Schiller, MD

Professor
Division of Hematology/Oncology
Department of Medicine
Director, Hematological Malignancy/Stem Cell Transplantation
David Geffen School of Medicine at UCLA
Los Angeles, California

Gary J. Schiller, MD, has disclosed that he has received funds for research support from Agios, Amgen, Astellas, Celator, Celgene, Daiichi, Gilead Sciences, Incyte, Karyopharm, Kite, MedImmune, Onconova, OxiGene, and Trovagene and holds ownership interests with Amgen, Novartis, and Pfizer.